Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability of Laquinimod in Adjunct to Glatiramer Acetate (GA) or Interferon-beta (IFN-β) in Relapsing Multiple Sclerosis (RMS) Subjects.

Next Previous
Trial Profile

A Phase II, Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability of Laquinimod in Adjunct to Glatiramer Acetate (GA) or Interferon-beta (IFN-β) in Relapsing Multiple Sclerosis (RMS) Subjects.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laquinimod (Primary) ; Glatiramer acetate; Interferon beta
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries

Most Recent Events

  • 26 Aug 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 15 Dec 2011 Planned initiation date changed from 1 Jul 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
  • 15 Dec 2011 Planned number of patients changed from 200 to 400 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top